Tracers / [11C]YM155
[11C]YM155
Also written as [11C]YM155; [C-11]YM155
- Radionuclide
- C-11 t½ 20.36 min
- Modality
- PET
- Production route
- —
- Stage
- —
- Syntheses indexed
- 1
What it is
- Compound class
- survivin suppressant small molecule (imidazolium-based compound)
- Target / mechanism
- Survivin PMID 23141550
- Clinical application
- Patients with various cancers (including non-Hodgkin lymphoma, lung cancer, and breast cancer) undergoing YM155 treatment, for prediction of tumor response PMID 30041149
- Theranostic pair
- —
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| — | — | — | 16-22% yes | >99% | ethanolamine-alkolate | 23141550 2013 Nucl Med Biol |
Need this precursor?We can point you to suppliers for [11C]YM155, or handle the enquiry for you.
Get in touchQuality control Preliminary — inferred from compound class
- Ph. Eur. monograph
- —
- USP monograph
- —
How this set was arrived at. base set per Ph. Eur. general monograph 0125 (rule); organic-phase radiosynthesis assumed from isotope/compound class, no synthesis data confirming it -> GC residual solvents (preliminary)
Tests listed by reference only. Monograph texts are copyrighted and are not reproduced here. How these are derived
Setting up quality control?We can help you scope the equipment needed to release [11C]YM155.
Get in touchNotes
Added from reverse module search (stage 6); 1 article(s) with C-11.